<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Trxade-Group-Inc-US89846A2078">Trxade Group Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 3 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/blockchain-and-cryptocurrency/datameds-ai-announces-updated-august-7-2026-record-date-for-distribut-1196613">DataMEDS AI kündigt aktualisiertes Record Date vom 7. August 2026 für die Verteilung der Dream Bowl 2026 Meme Coin an Aktionäre an</a>
    </div>

      <div class="me-0 me-md-5">
        TAMPA, FL / ACCESS Newswire / 27. Juli 2026 / DataMEDS AI, Inc., (NASDAQ:MEDS, &quot;DataMEDS,&quot; oder das &quot;Unternehmen&quot;), ein führendes Unternehmen für Gesundheitsinformations- technologie, das EinsteinRx™ KI-gestützte Rezeptsteuerung in die blockchainfähige Smart-Contract-Plattform PharmacyChain™ implementiert, um den Erstattungs- und Abgabeprozess für verschreibungspflichtige Medikamente zu optimie...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Trxade-Group-Inc-US89846A2078">Trxade Group Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/blockchain-and-cryptocurrency/datameds-ai-officially-begins-trading-under-stock-symbol-meds-on-the-1194701">DataMEDS AI beginnt offiziell unter dem Börsenkürzel &#39;MEDS&#39; am NASDAQ Capital Market zu handeln</a>
    </div>

      <div class="me-0 me-md-5">
        Handel unter neuem Kürzel (NASDAQ: MEDS) schließt Konzernrebranding vom früheren Firmennamen Wellgistics Health (NASDAQ: WGRX) ab TAMPA, FL / ACCESS Newswire / 22. Juli 2026 / DataMEDS AI, Inc., (NASDAQ:MEDS, &quot;DataMEDS&quot; oder das &quot;Unternehmen&quot;), ein Health-IT-Unternehmen, das seine KI-Plattform EinsteinRx™ und die blockchain-fähige Smart-Contracts-Plattform PharmacyChain™ nutzt, um integrierte L...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Trxade-Group-Inc-US89846A2078">Trxade Group Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 4 Monaten</div>
        <span class="me-2 new badge text-secondary bg-gray-200" data-bs-toggle="tooltip"
              data-bs-title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern."
              title="Automatisch aus dem Englischen übersetzt. Standardsprache in den Einstellungen ändern.">EN</span>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/07/09/3324768/0/en/SCIENTURE-Announces-Commercial-Inventory-Readiness-and-July-Shipments-of-REZENOPY-naloxone-hydrochloride-to-Wholesalers.html">SCIENTURE kündigt gewerbliche Lagerbereitschaft und Juli-Lieferungen von REZENOPY™ (Naloxon‑hydrochlorid) an Großhändler an</a>
    </div>

      <div class="me-0 me-md-5">
        Kommerzielle Verfügbarkeit wird im August erwartet, während das Unternehmen die Einführung des von der FDA zugelassenen Naloxon‑hydrochlorid‑Nasensprays mit der höchsten Dosis vorantreibt
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Trxade-Group-Inc-US89846A2078">Trxade Group Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/18/3314147/0/en/SCIENTURE-Expands-Arbli-Payor-Coverage-and-Commercial-Access-Adding-Approximately-12-5-Million-Covered-Lives-Nationwide.html">SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide</a>
    </div>

      <div class="me-0 me-md-5">
        Broader pharmacy access, channel expansion, and payer coverage position Arbli ™ for increased prescription volume and revenue growth
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Trxade-Group-Inc-US89846A2078">Trxade Group Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/09/3308798/0/en/SCIENTURE-Secures-Formulary-Coverage-for-REZENOPY-with-a-Large-National-Health-Plan-and-Expands-Commercial-Team.html">SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team</a>
    </div>

      <div class="me-0 me-md-5">
        Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Trxade-Group-Inc-US89846A2078">Trxade Group Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/06/02/3305134/0/en/SCIENTURE-Receives-U-S-Patent-Covering-REZENOPY-Naloxone-HCl-Nasal-Spray-10-mg-Strengthening-Intellectual-Property-Protection-Through-2041.html">SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041</a>
    </div>

      <div class="me-0 me-md-5">
        U.S. Naloxone Market: ~$141 million in annual sales and 9.4 million units annually COMMACK, NY, June 02, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel spe...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Trxade-Group-Inc-US89846A2078">Trxade Group Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/18/3296641/0/en/SCIENTURE-Reports-First-Quarter-2026-Financial-Results-and-Business-Update-Highlighted-by-Significant-Revenue-Growth-and-Gross-Margin-Expansion.html">SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion</a>
    </div>

      <div class="me-0 me-md-5">
        COMMACK, NY, May 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today provided a busi...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Trxade-Group-Inc-US89846A2078">Trxade Group Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">GlobeNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.globenewswire.com/news-release/2026/05/07/3289973/0/en/Scienture-Secures-11-0-Million-in-Non-Dilutive-Debt-Financing-to-Accelerate-Growth-of-Approved-Product-Portfolio-and-Advancement-of-R-D-Pipeline.html">Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&amp;D Pipeline</a>
    </div>

      <div class="me-0 me-md-5">
        Proceeds support commercialization of Arbli ™ , the first FDA-approved ready-to-use oral suspension for hypertension; and REZENOPY ™ , life-saving opioid overdose emergency treatment
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Trxade-Group-Inc-US89846A2078/load_more?page=6">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>